A recent EY-Parthenon / OPPI report outlines a bold growth trajectory for India’s pharmaceutical industry: from about $55 bn today to $130 bn by 2030, and potentially $450 bn by 2047, powered by innovation, policy support, and a rapidly expanding healthcare market.
Glimpse:
India’s pharmaceutical market is projected to swell to US$ 130 billion by 2030, according to economic and industry forecasts, driven by rising domestic demand, export growth, and government reforms. Looking further ahead, sector leaders paint a long-term vision where India’s pharma could reach US$ 450 billion by 2047, fueled by innovation, research, and global integration.
India’s pharmaceutical industry is gearing up for a transformative decade. Reports from top strategists suggest the domestic market currently around US$ 55 billion could more than double to US$ 120–130 billion by 2030. But that’s just the start. Looking ahead to mid-century, a vision laid out by EY-Parthenon and OPPI sees the sector potentially reaching an astonishing US$ 450 billion by 2047.
This ambitious growth rests on powerful drivers. Domestically, increased healthcare access, rising incomes, and government-backed initiatives like Ayushman Bharat are laying the foundation. Meanwhile, India’s strength in generic manufacturing is shifting toward more innovation-led models: biosimilars, complex generics, next-gen therapies.
But to hit the $450 bn milestone, the industry will need serious investment in R&D, talent development, and ecosystem building especially collaboration between pharma companies, academia, and government. Leaders also cite digitalisation, AI, and streamlined regulatory support as critical enablers.
If this trajectory comes to life, India won’t just remain the “pharmacy of the world” it’ll become a global pharma powerhouse, leading not just on volume, but on value.
“With innovation, digitalisation, and deeper collaboration, India can transform from being the world’s pharmacy to the world’s pharmaceutical powerhouse.”
By
HB Team
